SmartLabs announces a national expansion with the addition of 80,000 sq. feet in South San Francisco, California and $36 million in Series A funding.
Sign up for our email list to receive the latest SmartLabs news.
SmartLabs' Member Company Gritstone Oncology dosed its first patient an investigational immunotherapy directed at shared tumor-specific neoantigens.
SmartLabs' Member Company Gritstone Oncology has advanced two candidates into clinical development since its IPO last September.
SmartLabs' Member Company Kronos Bio brought in $105 million in venture investment through a financing round led by Vida Ventures and Omega Funds.
SmartLabs Member Company Gritstone Oncology has brought on industry veteran Vijay Yabannavar, Ph.D., as executive vice president of manufacturing and technical operations.
Nikon Instruments became a part of the SmartLabs community in Cambridge in order to test out a new imaging service it has been developing for regenerative medicine clients.
Traditional real estate doesn't allow early biotechs to grow rapidly and unexpectedly as the science progresses. Cue Biopharma found the solution to this challenge by joining SmartLabs.
Ahead of the Biotechnology Innovation Organization (BIO)’s annual conference, SmartLabs' Lisa LaMotta sat down with Partnering Insight to talk about some of the challenges entrepreneurs face when trying to start a company.
SmartLabs Member Company Gritstone Oncology will webcast an event with key opinion leaders who will present on neoantigen-based immunotherapy on Monday, June 3, 2019 from 6:30-8:00 a.m. CT in Chicago.
SmartLabs Member Company Cue Biopharma will begin human clinical testing of its lead drug candidate CUE-101, making the biotech a development-stage company.